

• •



2015 .

ACR -

IgG, , -

G, ,

per os - ,

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

- -

-

-

-

-

-

-

-

.....	4
.....	7
10.....	8
.....	8
.....	8
.....	8
.....	9
.....	10
.....	12
..... !	.12
..... !	.12
.....	12
.....	12
.....	13
- .....	17
.....	20
.....	21
.....	21
.....	21



(Good Practice Points – GPPs)

- 
- 

( )

( ).

- ( ) I (A)

• ( ) **II (B)**

• ( ) **III (C)**

• ( ) **IV (D)**

-

( )

3-

2-

:

• ( ) ;

• ;

• ( ) ;

• ( , ( ) , ( ) ).

:

**10**

08.2

10-20%

**II.**

6

6

6

6  
( - , ,  
) , . 6  
,  
,  
-6 , , ,  
, , , ,  
,  
.

(ACR, 2011) :

- 
- 

39°C  
, ; , ;  
;  
,  
- ( ) - , ,  
( ). 2-5 .  
, , ,  
, , , ,  
, ,  
( ) ,  
, « »

4-6

1-8

T

ST,

50%



( ), II, VII, X;

- 
- 
- 
- 

( 25-30% , - ), ( 100 / , ), (> 30-50 . 109/ ) (> 1 000 . 109/ ). IgM, IgG,

2  
 30% , 35% -  
 , 10% -  
 , 6,5 39%  
 , 64% - , 25% -  
 ( )  
 ( )  
 ; ,  
 ( ) ,  
 - ,  
 ( )  
 ), -  
 - ,  
 : -  
 , - ;  
 « » .

, ( )  
 3-  
 2- :

- ( ) ;
- ;
- ( ) ;

• ( , ( ) , ( ) ).

:

• ( )

( , );

• , HLA-B27, 6 ;

• ; , ; ; ;

;

• IgM 2- ,

3 .

(ACR, 2011)

:

• <7 10 ;

• ( )

>7 10 .

:

• ( ): 4;

- 4;

- ;

- <4 10 ;

- <2 10 .

• ( ): >1-

- <3- .

• ( 3- ): >8;

- >8;

- 2 ;

- 7 10 ;

- 5 10 .

:

: , , , , ,

, , , , ;

( ), ,

1.

2.

D  
( )

),  
•  
•

(D).  
1  
(A)  
10-30 / 3- , 5-  
( ) per os 0,5-2,0  
per os  
/ 4 .  
1 6 , 1 4 .  
(C):  
(A) 8 /  
> 30 12 /  
- < 30 1 2 .  
(C) 15-

3- ( ACR ) -

, 50% (A) 4 / 1 4 . - (D)

375 / <sup>2</sup> 4-

(C): 40 24 / <sup>2</sup> 1 -

2 0,4 / 2 1 .

,

:

- ( )
- ;
- ;
- , -
- ;
- .
- - ,
- « » , 7

( 2009 . 415 , 26 2011 . 1644 , 23 2010 . 541 ).

, . . .

- .

-28

-14

( )

—  
—

—  
—

—  
—

—  
—

—  
—

—  
—

—  
—

—  
—

—  
—

,

,

-

:

;

:

:

-

:

:

-

.

:

:

1,0 10<sup>9</sup>/ —

5-10 / /

3-5 ,

—

( ):

;

;

;

( ,

3,4

).

,

:

,

;

,

,

• — - + : 5  
/ / , ,

• — , « »:  
— ;  
— ;  
— , , , , ,  
( ), - ;  
— , ( ) ,  
, , ;  
— , , - ).

• ( ):  
— - + 15 / / ( )  
14-21 ;  
— 15 / / 14-21 ;  
— 50-100 / / 14 .

• , , -  
:  
— 5-10 / / 8 ,  
— 5 / / 12 14-21  
;  
— , IgG  
0,2-0,5 / / .

• :  
— , IgA,  
IgG, IgM 2-8 / 1 ;  
IgG, , 16 /

• 1,5 10<sup>9</sup> / :



— ( ) 5-10  
/ / 3-5 ( — )

• ( , ):  
— ( ) 5-10  
/ / ;

— 50-100 / /

• — :  
— 50-100 / / + 15 / / 5-  
7,5 / / .

:  
— 10-20 / / ;

— + 40-80 / / ;

— , IgA,  
IgM, IgG, 5 / 3 .

• ( ):  
— ;  
— ;  
— ( ,  
3- 4- ).

• :  
— ;  
— ;  
— .

• :  
— ;  
— .

• ( ) :  
— ;  
— , ;  
— , ;



•  $-1 \quad 2 \quad .$   
 •  $1 \quad 3 \quad .$   
 •  $, \quad , \quad -1 \quad 6 \quad .$   
 •  $2$   
 •  $-$   
 •  $,$   
 ( )  
 •  $-$   
 •  $-1 \quad .$   
 • ( , )  
 •  $-1 \quad 2 \quad :$   
 —  $,$   
 ;  
 —  $,$   
 ;  
 —  $,$   
 ;  
 • ( , , , , )  
 •  $-1 \quad 2 \quad :$   
 —  $,$   
 ;  
 —  $,$   
 ;  
 —  $,$   
 ;  
 • ( Ig A, M, G; , , , )  
 •  $-1 \quad 3 \quad .$   
 •  $-1 \quad 14 \quad .$   
 •  $-1 \quad 14 \quad ( , , , )$   
 •  $1,5 \cdot 10^9 / :$   
 —  $,$   
 ;

— ( )  
5 10 / 3-5 ,

• :  
— ( ) 5-  
10 / 3-5 , ;  
— ( 50-100 /  
);

— , ;  
• , :  
— , ;  
— ( ) ( , , ,  
);  
— + 15 / / , 15  
/ / , 50-100 / ;  
— ;  
—

• ( , , ,  
, , , , , ,  
)—1 2 ;  
— , , , ;  
— ;  
— ;  
—

• ( Ig A, M, G; , , )—1

• —1 3 . —1 2 .  
 • , —1 6 .  
 • 2  
 • — .

• « - ».

• :  
 — , .

• ,

• :

— ;

— ;

— ( );

— ;

— ( );

— ;

— ;

—

1.

2.

3.

4.

5.

3-

6.

3-

7.

8.

•

•

•

•

•

•

40%

50%

1% < 0,5%

(ACR, 2011):

- 
- 

- 1.
- 2.
3. Alexeeva E.I., Valieva S.I., Bzarova T.M. et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. *Clin Rheumatol.* 2011; 30: 1163–72.
4. Amor B., Dougados M., Listrat V. et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? *Rev Rhum Engl Ed.* 1995; 62: 10–5.
5. Beukelman T., Patkar N.M., Saag K.G. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res (Hoboken).* 2011; 63: 465–82.
6. Cassidy J.T. Textbook of pediatric rheumatology. 6th ed. *Philadelphia: Saunders.* 2011.
7. Dougados M., van der Linden S., Juhlin R. et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis Rheum.* 1991; 34: 1218–27.
8. Hafner R. Juvenile spondarthritis. Retrospective study of 71 patients. *Monatsschr Kinderheilkd.* 1987; 135: 41–6.
9. Horneff G., Burgos-Vargas R. Juvenile idiopathic arthritis. Subgroup characteristics and comparisons between rheumatoid arthritis-like subgroups and ankylosing spondylitis-like subgroups. *Clin Exp Rheumatol.* 2009; 27: S131–138.
10. Hussein A., Abdul-Khaliq H., von der Hardt H. Atypical spondyloarthritis in children: proposed diagnostic criteria. *Eur J Pediatr.* 1989; 148: 513–7.
11. Martini A. Systemic juvenile idiopathic arthritis. *Autoimmun Rev.* 2012; 12: 56–9.
12. Marzan K.A.B., Shaham B. Early juvenile idiopathic arthritis. *Rheum Dis Clin North Am.* 2012; 38: 355–72.

13. Otten M.H., Anink J., Spronk S. et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. *Ann Rheum Dis.* 2013; 72: 1806–12. Doi:10.1136/annrheumdis-2012-201991.
14. Petty R.E., Southwood T.R., Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol.* 2004; 31: 390–2.
15. Sandborg C., Mellins E.D. A new era in the treatment of systemic juvenile idiopathic arthritis. *N Engl J Med.* 2012; 367: 2439–40.
16. Wallace C.A., Giannini E.H., Huang B. et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken).* 2011; 63: 929–36.
17. Wallace C.A., Giannini E.H., Spalding S.J. et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. *Arthritis Rheum.* 2012; 64: 2012–21.